SS-31 (Elamipretide): Mitochondrial-Targeted Peptide

SS-31 (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2), also known as Elamipretide or Bendavia, is a synthetic tetrapeptide designed to target the inner mitochondrial membrane. It belongs to the Szeto-Schiller (SS) peptide family, named after the researchers who developed these mitochondria-targeting sequences at Weill Cornell Medical College.

The SS peptides share a common structural motif: alternating aromatic and basic residues that promote cell permeability and selective accumulation in mitochondria. SS-31 concentrates in the inner mitochondrial membrane at 1,000-5,000 fold over extracellular concentrations, driven by the mitochondrial membrane potential. This remarkable enrichment is achieved without a mitochondrial targeting sequence — instead, the peptide's physicochemical properties (cationic charge, aromatic character) drive spontaneous partitioning into the cardiolipin-rich inner membrane.

SS-31 has a molecular weight of approximately 639.8 Da and is water-soluble. It has generated significant research interest as a tool compound for studying mitochondrial dysfunction in aging, cardiac, renal, and neurological models.

SS-31's mechanism centers on its interaction with cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane.

**Cardiolipin binding:** SS-31 binds selectively to cardiolipin through electrostatic and hydrophobic interactions. Cardiolipin is essential for the structural organization of electron transport chain (ETC) complexes and supercomplexes. By interacting with cardiolipin, SS-31 stabilizes the optimal organization of ETC complexes, promoting efficient electron transfer and reducing electron leak.

**Reduced reactive oxygen species (ROS):** Mitochondrial ROS are generated primarily at complexes I and III of the ETC when electrons "leak" from the transport chain and react with molecular oxygen. By optimizing ETC organization through cardiolipin stabilization, SS-31 reduces this electron leak and consequently decreases mitochondrial ROS production. In cell models, SS-31 at nanomolar concentrations reduces mitochondrial superoxide by 30-60%.

**ATP production:** Efficient electron transport drives the proton gradient that powers ATP synthase. By reducing electron leak and maintaining ETC supercomplex integrity, SS-31 improves coupling efficiency between oxygen consumption and ATP production. This manifests as increased ATP output per unit of oxygen consumed in Seahorse XF respirometry assays.

**Cytochrome c interaction:** SS-31 also modulates the interaction between cytochrome c and cardiolipin. Under stress conditions, cardiolipin-cytochrome c interactions shift from electron transfer to peroxidase activity, contributing to membrane damage. SS-31 prevents this pathological shift, maintaining cytochrome c in its electron carrier function.

SS-31 has been studied extensively across multiple organ systems and disease models.

Several approaches exist for targeting mitochondria in research, each with distinct mechanisms:

**SS-31 (Elamipretide):** Targets cardiolipin in the inner mitochondrial membrane. Optimizes ETC supercomplex organization. Cell-permeable at nanomolar concentrations. Does not act as a direct antioxidant — instead, it reduces ROS production at the source by improving electron transport efficiency.

**MitoQ:** A ubiquinone molecule conjugated to a triphenylphosphonium (TPP+) cation for mitochondrial targeting. Acts as a direct antioxidant by scavenging ROS within the mitochondrial matrix. Does not affect ETC organization. The TPP+ moiety can depolarize mitochondria at high concentrations, which is a limitation.

**MOTS-c:** A mitochondrial-derived peptide that acts primarily through AMPK activation and nuclear gene regulation. Its mechanism is metabolic (folate cycle inhibition, AMPK activation) rather than structural (ETC optimization). MOTS-c and SS-31 target different aspects of mitochondrial biology.

**NAD+ precursors (NMN, NR):** These replenish cellular NAD+ pools, which support sirtuin activity and mitochondrial biogenesis. They act on a slower timescale (days to weeks for biogenesis) compared to SS-31's acute effects on existing mitochondria.

SS-31 is unique in its mechanism of directly stabilizing mitochondrial membrane architecture, making it a distinctive tool for studying ETC supercomplex biology and cardiolipin function.

SS-31 is a potent compound that works at low concentrations:

**In-vitro concentrations:** SS-31 is active at 1-100 nanomolar in cell culture — significantly lower than most peptide research compounds. Mitochondrial membrane potential (TMRM or JC-1 staining), ROS production (MitoSOX), ATP content (luminescent assays), and oxygen consumption rate (Seahorse XF) are the standard readouts.

**In-vivo concentrations:** Rodent studies typically use 0.5-5 mg/kg administered subcutaneously or intraperitoneally. For ischemia-reperfusion studies, administration occurs 30 minutes before ischemia or at the time of reperfusion. For aging studies, daily administration for 1-8 weeks is typical.

**Stability:** SS-31 contains a D-arginine residue and a dimethyltyrosine modification that confer proteolytic resistance. Lyophilized material is stable at -20°C for 12+ months. Reconstituted solutions are stable at 2-8°C for 14 days.

**Controls:** Include vehicle controls and, for mechanism studies, consider using SS-20 (a related SS peptide that does not bind cardiolipin) as a structural control to confirm cardiolipin dependence of observed effects.

*All materials are for research use only.*